Paloma Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Paloma Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,800	Closed	-$1.86M	–	2327
2019 Q1	$1.86M	Buy	+13,800	New	+$1.72M	0.05%	481
2018 Q4	–	Sell	-26,600	Closed	-$3.7M	–	1921
2018 Q3	$3.7M	Buy	+26,600	New	+$3.34M	0.07%	249
2018 Q1	–	Sell	-23,000	Closed	-$2.75M	–	2368
2017 Q4	$2.75M	Buy	+23,000	New	+$2.8M	0.04%	518
2015 Q3	–	Sell	-58,000	Closed	-$10.5M	–	2046
2015 Q2	$10.5M	Buy	+58,000	New	+$10M	0.2%	102

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's ALXN Position: Q1 2021 in Review

Paloma Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 7,200 shares — an estimated $1.13M sold.

Paloma Partners first reported a position in ALXN in Q2 2014 and held it in 20 quarters. The position peaked at $7.29M in Q3 2014. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Paloma Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Paloma Partners sold 7,200 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.13M.
Paloma Partners first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 20 quarters.
Paloma Partners's Alexion Pharmaceuticals position peaked at $7.29M in Q3 2014.
752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.